CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Robert Bradway

Chairman, Chief Executive Officer & President, Amgen

Search every verified Robert Bradway interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On Amgen's second-quarter 2026 earnings call, Bradway reported total revenues of $10.1 billion, a 10% year-over-year increase, driven by double-digit product volume growth. He stated that the company's six key growth drivers grew 26% year-over-year and accounted for 70% of quarterly product sales, with 22 products achieving double-digit sales growth and 17 products annualizing at over $1 billion. Bradway attributed the performance to the breadth and depth of the portfolio, saying it demonstrated the company's ability to grow through patent expirations and increased competition, and expressed confidence in reaching more patients in the second half of the year. During the call, Bradway discussed the company's business development strategy, saying it remains focused on four therapeutic areas and seeks to advance the best innovation whether generated internally or externally. He noted that Amgen is primarily looking at smaller, earlier-stage assets rather than late-stage trials, and addressed the design of the OCEANIA study for its Lp(a) candidate, highlighting its double-blind, randomized controlled design with 7,297 patients enrolled and a primary endpoint of three-point MACE. Bradway also acknowledged the transition of CFO responsibilities from Peter Griffith to Thomas Dietz, thanking Griffith for his contributions to Amgen's financial foundation and investments in research, acquisitions, and technology.

Recent appearances

Notable quotes

“I read a lot and hear a lot about people expressing frustration that they're not earning a return from the investments that they're making. I'm a little bit puzzled by that. We're pretty early on this journey now. Maybe my bewilderment reflects the fact that in our industry again we invest 10 or 15 years in a molecule and you know two and a half billion dollars before we learn whether it's successful or not. So we ma”

“We've lowered the list price of Repatha twice; for the benefit it provides in terms of reducing heart attack and stroke risk, nobody in the United States will pay more than $8 a day for access to Repatha and most patients are paying a small fraction of that amount.”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →